Sopharma AD (WSE:SPH)

Market Cap	3.11B
Revenue (ttm)	5.47B
Net Income (ttm)	270.79M
Shares Out	n/a
EPS (ttm)	0.97
PE Ratio	11.50
Forward PE	n/a
Dividend	0.36 (2.85%)
Ex-Dividend Date	Dec 18, 2025

Volume	2,082
Average Volume	816
Open	13.65
Previous Close	13.00
Day's Range	12.45 - 13.90
52-Week Range	3.80 - 16.00
Beta	-0.09
RSI	68.34
Earnings Date	Nov 30, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1933
• Employees: 5,599
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SPH

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.

Financial numbers in BGN